Emcure Pharmaceuticals Ltd (Emcure) develops, manufactures and markets a diverse range of pharmaceutical products.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Emcure's research and development (R&D) activities are centered on developing complex drug delivery systems, such as sustained-release formulations, liposomal injections, and advanced dermal therapies. It is actively investing in next-generation platforms, including Antibody Drug Conjugates (ADCs), biosimilars, long-acting injectables, peptides, and novel drug delivery systems (NDDS). An R&D centre specialises in API research, while three focus on formulations and another on biopharmaceuticals. The company is a pioneer in chiral chemistry, having developed and marketed six chiral molecules that offer enhanced effectiveness, safety, and reduced dosages compared to non-chiral alternatives. Emcure Pharmaceuticals Ltd has established multiple R&D units, including the Emcure Research Centre in Gujarat and a state-of-the-art Formulation Research and Development Centre near Tapovan Circle, Ahmedabad. Its R&D units focus on various dosage forms, including oral solids, oral liquids, inhalers, injectables, NDDS, and topical/transdermal delivery systems. The company operates five R&D centers and has been granted 234 patents. Its R&D pipeline includes a range of products across therapeutic areas such as Diabetology, Obesity, Oncology, Women Health, CNS, Dermatology, and Anti-Infectives. Emcure’s R&D expertise extends to complex generics, oncology products, iron molecules, antiretrovirals, hormones, and immunosuppressants. The company has a state-of-the-art facility for producing immunosuppressant APIs. In formulations, Emcure focuses on developing multiple dosage forms and novel drug delivery systems to enhance patient compliance. Its strong in-house R&D capabilities have enabled the company to create a differentiated portfolio of pharmaceutical products, providing a competitive edge in the global markets where it operates. In FY2025, the company spent INR1,713 million on R&D, which as a percentage of revenue stood at 2%.